Core Insights - Humana Inc. is a significant player in the health insurance sector, particularly known for its Medicare offerings, competing with major insurers like UnitedHealth Group and Anthem [1] - Barclays analyst Andrew Mok has set a price target of $234 for Humana, indicating a potential upside of approximately 2.09% from its current trading price of $229.20 [2][6] - Berman Tabacco, a national law firm, is investigating Humana for potential illegal kickbacks to insurance brokers, with allegations involving up to $250 million paid to influence broker decisions [3][4][6] Financial Performance - Humana's stock is currently priced at $229.20, reflecting an increase of approximately 0.92% or $2.10, with a market capitalization of around $27.57 billion [5][6] - The stock has experienced fluctuations, with a low of $222.04 and a high of $229.82 during the trading day, and over the past year, it reached a high of $315.35 and a low of $206.87 [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of misleading practices related to Medicare insurance plans and illegal kickbacks [3][5][6] Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of quality [5] - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans [5] - SelectQuote allegedly received illegal kickbacks from health insurers to steer beneficiaries towards certain plans, limiting enrollment in competitors' offerings [5] - The company is accused of violating federal laws, including the False Claims Act, due to its conduct [5][6] - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021 [6] Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [6] - Investors are reminded of the October 10, 2025 deadline to seek the role of lead plaintiff in the federal securities class action against SelectQuote [3][7]